Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Lancet Haematol
; 8(4): e254-e266, 2021 Apr.
Article
in En
| MEDLINE
| ID: mdl-33631112
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperidines
/
Adenine
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
/
Asia
Language:
En
Journal:
Lancet Haematol
Year:
2021
Document type:
Article